A novel bioassay model to determine clinically significant bisphosphonate levels

Supportive Care in Cancer

Volumn 17, Issue 12, 2009, Pages 1553-1557

  Scheper, Mark A ^a,b   Badros, Ashraf ^b   Salama, Andrew R ^a,b   Warburton, Gary ^b   Cullen, Kevin J ^b   Weikel, Dianna S ^a,b   Meiller, Timothy F ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Bioassay; Bisphosphonate; Bone; Epithelium; Saliva

Indexed keywords

ZOLEDRONIC ACID;

ADULT; ARTICLE; BIOASSAY; BONE EXAMINATION; BONE NECROSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BONE LEVEL; DRUG SALIVA LEVEL; EX VIVO STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SALIVA ANALYSIS;

ADULT; APOPTOSIS; BIOLOGICAL ASSAY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CELL LINE; CELL PROLIFERATION; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MOUTH MUCOSA; OSTEONECROSIS; RISK FACTORS; SALIVA;

EID: 71349088410     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0710-7     Document Type: Article

References (17)

1. A Badros E Terpos E Katodritou O Goloubeva E Kastritis E Verrou K Zervas MR Baer T Meiller MA Dimopoulos 2008 Natural history of osteonecrosis of the jaw in patients with multiple myeloma J Clin Oncol 26 5904 5909 10.1200/JCO.2008.16.9300 19018084
2. A Badros D Weikel A Salama O Goloubeva A Schneider A Rapoport R Fenton N Gahres E Sausville R Ord T Meiller 2006 Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 945 952 10.1200/JCO.2005.04.2465 1:CAS:528:DC%2BD28Xitl2qt7o%3D 16484704 (Pubitemid 46638849)
3. JV Bagan Y Jimenez J Murillo S Hernandez R Poveda JM Sanchis JM Diaz C Scully 2006 Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases Oral Oncol 42 327 329 10.1016/j.oraloncology.2005.08.001 16275156 (Pubitemid 43246766)
4. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas V Koutsoukou D Gika A Anagnostopoulos C Papadimitriou E Terpos MA Dimopoulos 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587 10.1200/JCO.2005.02.8670 16314620 (Pubitemid 46211499)
5. JP Bilezikian 2006 Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 355 2278 2281 10.1056/NEJMp068157 1:CAS:528: DC%2BD28Xht1yitLzM 17135582 (Pubitemid 44837776)
6. SC Cremers G Pillai SE Papapoulos 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis Clin Pharmacokinet 44 551 570 10.2165/00003088-200544060-00001 1:CAS:528:DC%2BD2MXmsFKrtL8%3D 15932344 (Pubitemid 40994085)
7. C Dannemann R Zwahlen KW Gratz 2006 Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws Swiss Med Wkly 136 504 509 1:CAS:528:DC%2BD28XhtVKnsbbM 16947089
8. JA Kanis 1995 Bone and cancer: pathophysiology and treatment of metastases Bone 17 101S 105S 10.1016/8756-3282(95)00194-I 1:CAS:528: DyaK2MXns1Ogsbw%3D 8579890
9. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg RF Gagel V Gilsanz T Guise S Koka LK McCauley J McGowan MD McKee S Mohla DG Pendrys LG Raisz SL Ruggiero DM Shafer L Shum SL Silverman CH Van Poznak N Watts SB Woo E Shane 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 10.1359/jbmr.0707onj 17663640 (Pubitemid 351229318)
10. KO Klein J Baron KM Barnes OH Pescovitz GB Cutler Jr 1998 Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist J Clin Endocrinol Metab 83 2387 2389 10.1210/jc.83.7.2387 1:CAS:528:DyaK1cXksVSju7g%3D 9661615 (Pubitemid 28503034)
11. T Mavrokokki A Cheng B Stein A Goss 2007 Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 415 423 10.1016/j.joms.2006.10.061 17307586 (Pubitemid 46343586)
12. H Noedl P Teja-Isavadharm RS Miller 2004 Nonisotopic, semiautomated Plasmodium falciparum bioassay for measurement of antimalarial drug levels in serum or plasma Antimicrob Agents Chemother 48 4485 4487 10.1128/AAC.48.11.4485- 4487.2004 1:CAS:528:DC%2BD2cXpvVyktLY%3D 15504891 (Pubitemid 39434925)
13. MJ Rogers DJ Watts RG Russell 1997 Overview of bisphosphonates Cancer 80 1652 1660 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0. CO;2-Z 1:CAS:528:DyaK2sXmvFyht7s%3D 9362432
14. MA Scheper A Badros R Chaisuparat KJ Cullen TF Meiller 2009 Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis Br J Haematol 144 667 676 10.1111/j.1365-2141.2008.07504.x 1:CAS:528:DC%2BD1MXktVeltbk%3D 19036117
15. A Skerjanec J Berenson C Hsu P Major WH Miller Jr C Ravera H Schran J Seaman F Waldmeier 2003 The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function J Clin Pharmacol 43 154 162 10.1177/0091270002239824 1:CAS:528:DC%2BD3sXht1eqsLo%3D 12616668 (Pubitemid 36125942)
16. M Witvrouw M Baba J Balzarini R Pauwels E De Clercq 1990 Establishment of a bioassay to determine serum levels of dextran sulfate and pentosan polysulfate, two potent inhibitors of human immunodeficiency virus J Acquir Immune Defic Syndr 3 343 347 1:CAS:528:DyaK3cXitFSntLs%3D 1690285
17. SB Woo JW Hellstein JR Kalmar 2006 Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 761 1:CAS:528:DC%2BD28XlsFKhs70%3D 16702591